Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

1.

Clinical drug development for childhood cancers.

Balis FM, Fox E, Widemann BC, Adamson PC.

Clin Pharmacol Ther. 2009 Feb;85(2):127-9. doi: 10.1038/clpt.2008.237. No abstract available.

PMID:
19151636
[PubMed - indexed for MEDLINE]
2.

Dipeptide boronic acid inhibitors of dipeptidyl peptidase IV: determinants of potency and in vivo efficacy and safety.

Connolly BA, Sanford DG, Chiluwal AK, Healey SE, Peters DE, Dimare MT, Wu W, Liu Y, Maw H, Zhou Y, Li Y, Jin Z, Sudmeier JL, Lai JH, Bachovchin WW.

J Med Chem. 2008 Oct 9;51(19):6005-13. doi: 10.1021/jm800390n. Epub 2008 Sep 11.

PMID:
18783201
[PubMed - indexed for MEDLINE]
3.

Talabostat.

Cunningham CC.

Expert Opin Investig Drugs. 2007 Sep;16(9):1459-65. Review.

PMID:
17714031
[PubMed - indexed for MEDLINE]
4.

Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy.

Nemunaitis J, Vukelja SJ, Richards D, Cunningham C, Senzer N, Nugent J, Duncan H, Jones B, Haltom E, Uprichard MJ.

Cancer Invest. 2006 Oct;24(6):553-61.

PMID:
16982458
[PubMed - indexed for MEDLINE]
5.

Methodology of clinical trials with new molecular-targeted agents: where do we stand?

Morabito A, Di Maio M, De Maio E, Normanno N, Perrone F.

Ann Oncol. 2006 Jun;17 Suppl 7:vii128-31. Review.

PMID:
16760275
[PubMed - indexed for MEDLINE]
Free Article
6.

Dose escalation trial designs based on a molecularly targeted endpoint.

Hunsberger S, Rubinstein LV, Dancey J, Korn EL.

Stat Med. 2005 Jul 30;24(14):2171-81.

PMID:
15909289
[PubMed - indexed for MEDLINE]
7.

PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibody-mediated cytotoxicity via a novel immune mechanism.

Adams S, Miller GT, Jesson MI, Watanabe T, Jones B, Wallner BP.

Cancer Res. 2004 Aug 1;64(15):5471-80.

PMID:
15289357
[PubMed - indexed for MEDLINE]
Free Article
8.

Cell-surface peptidases.

Mentlein R.

Int Rev Cytol. 2004;235:165-213. Review.

PMID:
15219783
[PubMed - indexed for MEDLINE]
9.

Clinical trial design for target specific anticancer agents.

Hoekstra R, Verweij J, Eskens FA.

Invest New Drugs. 2003 May;21(2):243-50. Review.

PMID:
12889742
[PubMed - indexed for MEDLINE]
11.

Clinical trial design for target-based therapy.

Fox E, Curt GA, Balis FM.

Oncologist. 2002;7(5):401-9. Review.

PMID:
12401902
[PubMed - indexed for MEDLINE]
Free Article
12.

Novel endpoints and design of early clinical trials.

Parulekar WR, Eisenhauer EA.

Ann Oncol. 2002;13 Suppl 4:139-43. Review. No abstract available.

PMID:
12401680
[PubMed - indexed for MEDLINE]
Free Article
13.

A kinetic fluorometric assay of dipeptidyl peptidase IV in viable human blood mononuclear cells.

Sedo A, Krepela E, KasafĂ­rek E.

Biochimie. 1989 Jun;71(6):757-61.

PMID:
2568856
[PubMed - indexed for MEDLINE]
14.

Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

Garin-Chesa P, Old LJ, Rettig WJ.

Proc Natl Acad Sci U S A. 1990 Sep;87(18):7235-9.

PMID:
2402505
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk